XSHG
600299
Market cap3.84bUSD
Oct 09, Last price
8.48CNY
1D
1.56%
1Q
7.34%
Jan 2017
-41.07%
IPO
11.14%
Name
Bluestar Adisseo Co
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bluestar Adisseo Company operates as a global leader in the development, production, and distribution of specialized feed additives for animal nutrition. The company's diverse product portfolio includes Rhodimet, a range of methionine-based solutions for monogastric animals, offered in both solid (Rhodimet NP99) and liquid (Rhodimet AT88) forms. Additionally, it provides advanced nutritional formulas, such as Smartamine and MetaSmart, which are engineered to ensure optimal amino acid balance in the diets of lactating dairy cows and other ruminants. Its Microvit range offers a comprehensive selection of vitamins essential for the feed industry. Adisseo also produces a diverse array of enzyme preparations under the Rovabio brand, formulated to enhance the digestibility of plant-based raw materials for various animal species, including poultry and swine. Another significant offering is Selisseo 2% Se, an organic selenium source based on seleno-hydroxy-methionine, designed for integration into animal feed. The firm supplies AdiSodium, a chloride-free sodium alternative that supports dietary electrolyte balance in monogastric feeds and delivers an assimilable form of sulfur to ruminant diets. Furthermore, Alterion is provided to improve animal gut health and overall performance by fostering a balanced intestinal micro-ecosystem. Complementing its product portfolio, the company provides several specialized services. PNE utilizes Near-Infrared (NIR) technology to accurately predict the nutritional quality of feed raw materials. DiM offers dedicated assistance and application support for its Rhodimet AT88 product. Lastly, E-lab is an online portal facilitating analytical requests and simplifying sample identification for customers prior to shipment to Adisseo's laboratories. Founded in 1939 and headquartered in Beijing, China, Bluestar Adisseo Company functions as a subsidiary of China National Bluestar (Group) Co., Ltd.
Key people
Zhigang Hao
Chairman of the Board, Chief Executive Officer, General Manager · since 2024
Vice Chairman of the Board · since 2023
Chief Financial Officer · since 2023
Frederic Jacquin
Chief Operating Officer, Deputy General Manager · since 2022
Bingjing Ding
Deputy General Manager · since 2025
Jean-Francois Rous
Deputy General Manager · since 2023
Fabien Siguier
Deputy General Manager · since 2023
Xiaolei Zhu
Deputy General Manager · since 2024
Yun Cai
Secretary of the Board · since 2023
Director · since 2018
Dachuan Dong
Director · since 2024
Yong Pan
Staff Elected Director · since 2025
Yanfeng Sun
Director · since 2023
Wei Yao
Director · since 2024
Independent Director · since 2024
Xin Liu
Independent Director · since 2024
Zhixiang Sun
Independent Director · since 2025
Hengchang Zang
Independent Director · since 2021
Headquarters & legal address
北京市海淀区花园东路30号北京海淀花园饭店6518室
海淀区, BJ 100000
CN
海淀区, BJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||